The role of c-Jun and c-Fos expression in androgen-independent prostate cancer

Journal of Pathology

Volumn 204, Issue 2, 2004, Pages 153-158

  Edwards, Joanne ^a   Krishna, N Sarath ^a   Mukherjee, Rono ^a   Bartlett, John M S ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Androgen insensitive prostate cancer; AP 1; c Fos; c Jun; Protein kinase C

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BIOCHEMISTRY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SCORING SYSTEM;

AGED; ANDROGENS; HUMANS; MALE; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSCRIPTION FACTOR AP-1;

EID: 5044238301     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1605     Document Type: Article

References (22)

1. Cancer Research UK Website. Cancer Stats. Mortality-UK. www.cancerresearchuk.org (2004).
2. Trachtenberg J, Blackledge G. Looking to the future: advances in the management of hormone-refractory prostate cancer. Eur Urol Suppl 2002; 1: 44-53.
3. Sumitomo M, Milowsky MI, Shen R, et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001; 61: 3294-3298.
4. Bonaccorsi L, Muratori M, Carloni V, et al. Androgen receptor and prostate cancer invasion. Int J Androl 2003; 26: 21-25.
5. Sato N, Sadar MD, Bruchovsky N, et al. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP. J Biol Chem 1997; 272: 17 485-17 494.
6. Bubulya A, Chen SY, Fisher CJ, Zheng Z, Shen XQ, Shemshedini L. c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. J Biol Chem 200 1; 276: 44 704-44 711.
7. Lubahn DB, Brown TR, Simental JA, et al. Sequence of the intron exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Nat Acad Sci U S A 1989; 86: 9534-9538.
8. Behrens A, Jochum W, Sibilia M, Wagner EF. Oncogenic transformation by Ras and Fos is mediated by c-Jun N-terminal phosphorylation. Oncogene 2000; 19: 2657-2663.
9. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. Requirement of c-Jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis. Mol Carcin 2003; 36: 115-122.
10. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer; molecular biology of early progression to androgen independence. Endocrine Related Cancer 1999; 6: 487-502.
11. Wang Q, Lu J, Yong EL. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 2001; 276: 7493-7499.
12. Wise SC, Burmeister LA, Zhou XF, et al. Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene 1998; 16: 2001-2009.
13. Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L. c-Jun can mediate androgen receptor-induced transactivation. J Biol Chem 1996; 271: 24 583-24 589.
14. Fronsdal K, Engedal N, Slagsvold T, Saatcioglu F. CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J Biol Chem 1998; 273: 31 853-31 859.
15. Tillman K, Oberfield JL, Shen XQ, Bubulya A, Shemshedini L. c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation. Endocrine 1998; 9: 193-200.
16. Edwards J, Krishna NS, Bartlett JMS. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89: 552-556.
17. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev 2001; 1: 34-45.
18. Sun M, Yang L, Feldman RI, et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of P85 alpha, androgen receptor, and Src. J Biol Chem 2003; 278: 42 992-43 000.
19. Edwards J, Krishna NS, Witton CJ, Bartlett JMS. Gene amplifications associated with the development of hormone resistant prostate cancer. Clin Cancer Res 2003; 9: 5271-5281.
20. Tanaka Y, Gavrielides MV, Mitsuuchi Y, Fujii T, Kazanietz MG. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of P38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 2003; 278: 33 753-33 762.
21. Mackay HJ, Twelves CJ. Protein kinase C: a target for anticancer drugs? Endocrine-Related Cancer 2003; 10: 389-396.
22. Gioeli D, Ficarro SB, Kwiek JJ, et al. Androgen receptor phosphorylation - regulation and identification of the phosphorylation sites. J Biol Chem 2002; 277: 29 304-29 314.